Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

New Diabetes Drug Fights Obesity While Controlling Glucose Metabolism

By BiotechDaily International staff writers
Posted on 11 Nov 2013
A synthetic peptide that targets receptors for the naturally occurring incretin hormones GLP-1 and GIP is being developed into a drug for the management of diseases associated with impaired glucose tolerance.

Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating, even before blood glucose levels become elevated. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. They also inhibit glucagon release from the alpha cells of the Islets of Langerhans.

The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (also known as glucose-dependent insulinotropic polypeptide or GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

Investigators at Indiana University (Bloomington, USA) developed a "unimolecular dual incretin" derived from an intermixed peptide sequence from GLP-1 and GIP. They reported in the October 30, 2013, online edition of the journal Science Translational Medicine that this compound corrected two causal mechanisms of diabetes-linked obesity, i.e., adiposity-induced insulin resistance and pancreatic insulin deficiency, more effectively than did selective mono-agonists. This superior efficacy translated across rodent models of obesity and diabetes, including db/db mice and ZDF rats, to primates (cynomolgus monkeys and humans).

"The current study demonstrates clearly that combining GLP-1 and GIP can produce improved therapeutic effects," said contributing author Dr. Richard DiMarchi, professor of chemistry at Indiana University. "It achieved results comparable to those that resulted from a 10-fold higher dose of agents that target only GLP-1 receptors."

"The results demonstrate that GLP-1 and GIP, when built into a single molecule, provide synergistic activity to control glucose and lower body weight across a spectrum of animal models, including in human clinical experiments," said Dr. DiMarchi. "Currently approved drugs are quite effective, but they are insufficient in normalizing glucose, and they certainly do not cause much loss of body weight."

Clinical trials conducted by Roche (Basel, Switzerland) demonstrated a decrease in glucose levels beyond what would be expected from conventional treatment. However, the six-week trial was not of significant duration to provide definitive evidence about weight loss in humans.

Related Links:

Indiana University
Roche 



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A leukemia cell coated with antibody is marked for destruction by activated natural killer cells (Photo courtesy of the University of Southern California).

Leukemia Cells Are Killed in Culture by Immune Cells Grown from the Same Patient

Immune system natural killer (NK) cells were isolated from leukemia patients, expanded in culture, and then shown in an in vitro system to attack and destroy cancer cells from the original cell donors.... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

White-Matter Deficits Found in Codeine-Containing Cough Syrup Users

A magnetic resonance imaging (MRI) study of chronic users of codeine-containing cough syrups (CCS) has found deficits in specific regions of brain white matter and linked these changes with increased impulsivity in codeine-containing cough syrup users. These findings were consistent with findings from earlier research of... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.